BILBAO, Spain – The coming months will be a crucial period in the development of Zeltia Group, Spain's flagship biotechnology company, which is due to report data from several clinical trials, including a Phase IIb trial of Nypta (tideglusib) in Alzheimer's disease and a Phase III trial of Aplidin (ptilidepsin) in multiple myeloma. Read More
LONDON – New therapies for conditions such as cardiac hypertrophy and heart failure could be developed as a result of a better understanding of the minute regulation of gene transcription in heart muscle cells. Read More
LONDON – A new-look, 80-strong small-molecule drug discovery and development company has emerged from Abbott, following the management buyout of the former Solvay Pharmaceuticals R&D laboratory in Dijon, France. Read More
TopoTarget A/S' positive results from the BELIEF pivotal trial with belinostat could mean upside for U.S. partner Spectrum Pharmaceuticals Inc., if the histone deacetylase (HDAC) inhibitor is approved for peripheral T-cell lymphoma, but the latest outcome with belinostat is "not really a game changer for this drug," said Decision Resources analyst Lisa Murch. Read More
LONDON – Advanced Accelerator Applications SA has set itself the challenge of servicing 42 centers across the U.S. and Europe, in a 200-patient Phase III trial of Lutathera, a radiolabeled peptide that has a shelf life of only 72 hours. Read More
BILBAO, Spain – Visitors to the opening day of BioSpain 2012 last week had to pass through airport-style security in the foyer of the Bilbao Exhibition Center (BEC). Read More
• Aprea AB, of Stockholm, Sweden, reported positive data from a Phase I/II study with investigational drug APR-246. In the trial, escalating doses of APR-246 were administered as a monotherapy to 22 patients with advanced blood or prostate cancer for up to four consecutive days. Dose-limiting toxicity was shown at plasma levels well above predicted therapeutic plasma levels. Read More
